EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

(15:53)

Aero-TV At SnF21: Electrifying The Aerolite EV-103

(3:8)

Aerolite EV-103 Electric powered aircraft - First Owner Review at Oshkosh 2021

(9:35)

Aerolite EV-103, ** Its ELECTRIC ! ** Ultralight Aircraft

(23:56)

EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma

(13:47)

EV 103 Kontsertaktus

(1:31:37)

Dr. Hoimes on EV-103 Results in Urothelial Cancer

(53)

EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma

(6:2)

AerolitE 103, Aerolite 103 electric powered, part 103 legal, ultralight, Dennis Carley, UFLYIT.

(12:)

Drs. Friedlander, Koshkin on Long-Term Follow-Up of EV-103

(9:54)

EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC

(2:20)

EV 103 - EVannex University

(9:34)

Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma

(2:10)

Sun 'n Fun 2021 Aerolite 103 Offers an Electric Kit Version

(2:42)

EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBC

(2:9)

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

(8:)

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

(1:7)

EV-103 Cohort H: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible MIBC

(1:24)